

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	658060-00017	Date of first issue: 03.05.2016

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Furosemide Solid Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road
Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Specific target organ toxicity - : Category 1 (Kidney, Liver)
repeated exposure

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H372 Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Precautionary statements : **Prevention:**
P260 Do not breathe dust.
P264 Wash hands thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

SAFETY DATA SHEET

according to the Globally Harmonized System



Furosemide Solid Formulation

Version 5.1 Revision Date: 14.04.2025 SDS Number: 658060-00017 Date of last issue: 28.09.2024
Date of first issue: 03.05.2016

Response:

P319 Get medical help if you feel unwell.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Starch	9005-25-8	≥ 50 - < 70
Furosemide	54-31-9	≥ 10 - < 20
Cellulose	9004-34-6	≥ 1 - < 5

4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
Causes damage to organs through prolonged or repeated exposure.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam

SAFETY DATA SHEET

according to the Globally Harmonized System



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	658060-00017	Date of first issue: 03.05.2016

	Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Nitrogen oxides (NO _x) Carbon oxides Sulphur oxides Chlorine compounds
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Furosemide Solid Formulation

Version 5.1 Revision Date: 14.04.2025 SDS Number: 658060-00017 Date of last issue: 28.09.2024
Date of first issue: 03.05.2016

7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Starch	9005-25-8	TWA	10 mg/m ³	ACGIH
Furosemide	54-31-9	TWA	200 µg/m ³	Internal
		TWA	OEB 2 (>=100 - 1000 µg/m ³)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH

- Engineering measures** : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection : Chemical-resistant gloves

SAFETY DATA SHEET

according to the Globally Harmonized System



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	658060-00017	Date of first issue: 03.05.2016

- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : powder
- Colour : yellow
- Odour : No data available
- Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : Not applicable
- Evaporation rate : No data available
- Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
- Flammability (liquids) : No data available
- Upper explosion limit / Upper flammability limit : No data available
- Lower explosion limit / Lower flammability limit : No data available
- Vapour pressure : No data available
- Relative vapour density : No data available

SAFETY DATA SHEET

according to the Globally Harmonized System



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	658060-00017	Date of first issue: 03.05.2016

Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	Not applicable
Particle characteristics	:	
Particle size	:	No data available

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg
---------------------	---	--

SAFETY DATA SHEET

according to the Globally Harmonized System



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	658060-00017	Date of first issue: 03.05.2016

Method: Calculation method

Components:

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Furosemide:

Acute oral toxicity : LD50 (Rat): 2,600 mg/kg

LD50 (Dog): 2,000 mg/kg

LD50 (Rabbit): 800 mg/kg

Acute toxicity (other routes of administration) : LD0 (Humans): 6 - 29 mg/kg
Application Route: Intravenous

LD50 (Rat): 800 mg/kg
Application Route: Intravenous

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Starch:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

SAFETY DATA SHEET

according to the Globally Harmonized System



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	658060-00017	Date of first issue: 03.05.2016

Components:

Starch:

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Result	:	negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Starch:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	--

Furosemide:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: In vitro mammalian cell gene mutation test Test system: mouse lymphoma cells Result: positive Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Test system: mammalian liver cells Result: negative Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells Result: positive Test Type: In vitro sister chromatid exchange assay in mammalian cells Test system: Chinese hamster cells Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Chinese hamster Application Route: Ingestion Result: negative

Cellulose:

SAFETY DATA SHEET

according to the Globally Harmonized System



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	658060-00017	Date of first issue: 03.05.2016

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Furosemide:

Species : Rat
Application Route : Ingestion
Exposure time : 104 weeks
LOAEL : 16 mg/kg body weight
Result : equivocal

Species : Mouse
Application Route : Ingestion
Exposure time : 2 Years
LOAEL : 91 mg/kg body weight
Result : positive

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Furosemide:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
General Toxicity - Parent: NOAEL: 90 mg/kg body weight
Result: No effects on reproduction parameters

Test Type: One-generation reproduction toxicity study
Species: Mouse
Application Route: Ingestion
General Toxicity - Parent: NOAEL: 200 mg/kg body weight
Result: No effects on reproduction parameters

SAFETY DATA SHEET

according to the Globally Harmonized System



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	658060-00017	Date of first issue: 03.05.2016

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 50 mg/kg body weight
Developmental Toxicity: NOAEL: 300 mg/kg body weight
Result: No embryotoxic effects, No teratogenic effects

Test Type: Fertility/early embryonic development
Species: Mouse
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 25 mg/kg body weight
Result: Maternal toxicity observed., Fetal effects

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: \leq 12 mg/kg body weight
Developmental Toxicity: LOAEL: 12.5 mg/kg body weight
Result: Maternal toxicity observed., Reduced number of viable fetuses

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 15 mg/kg body weight
Result: Maternal toxicity observed., No effects on foetal development

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Components:

Furosemide:

Exposure routes : Ingestion
Target Organs : Kidney
Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

SAFETY DATA SHEET

according to the Globally Harmonized System



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	658060-00017	Date of first issue: 03.05.2016

Repeated dose toxicity

Components:

Starch:

Species	: Rat
NOAEL	: $\geq 2,000$ mg/kg
Application Route	: Skin contact
Exposure time	: 28 Days
Method	: OECD Test Guideline 410

Furosemide:

Species	: Dog
NOAEL	: 4 mg/kg
LOAEL	: 8 mg/kg
Application Route	: Ingestion
Exposure time	: 12 Months
Target Organs	: Kidney
Symptoms	: Blood disorders
Remarks	: Significant toxicity observed in testing

Cellulose:

Species	: Rat
NOAEL	: $\geq 9,000$ mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Furosemide:

Inhalation	: Remarks: May be harmful if inhaled.
Skin contact	: Remarks: May irritate skin.
Eye contact	: Remarks: May cause eye irritation.
Ingestion	: Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Furosemide:

Toxicity to fish	: LC50: 500 mg/l Exposure time: 96 h
------------------	---

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	658060-00017	Date of first issue: 03.05.2016

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Bioaccumulative potential

Components:

Furosemide:

Partition coefficient: n-octanol/water : log Pow: 2.03

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

SAFETY DATA SHEET

according to the Globally Harmonized System



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	658060-00017	Date of first issue: 03.05.2016

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 14.04.2025

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances

SAFETY DATA SHEET

according to the Globally Harmonized System



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	658060-00017	Date of first issue: 03.05.2016

es; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN